{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:08:02Z","timestamp":1779149282568,"version":"3.51.4"},"reference-count":36,"publisher":"American Society for Clinical Investigation","issue":"18","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>New therapeutic combinations to improve outcomes of patients with ovarian cancer are clearly needed. Preclinical studies with ribociclib (LEE-011), a CDK4\/6 cell cycle checkpoint inhibitor, demonstrate a synergistic effect with platinum chemotherapy and efficacy as a maintenance therapy after chemotherapy. We tested the safety and initial efficacy of ribociclib in combination with platinum-based chemotherapy in recurrent ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This phase I trial combined weekly carboplatin and paclitaxel chemotherapy with ribociclib, followed by ribociclib maintenance in patients with recurrent platinum-sensitive ovarian cancer. Primary objectives were safety and maximum tolerated dose (MTD) of ribociclib when given with platinum and taxane chemotherapy. Secondary endpoints were response rate (RR) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Thirty-five patients were enrolled. Patients had a mean of 2.5 prior lines of chemotherapy, and 51% received prior maintenance therapy with poly(ADP-ribose) polymerase inhibitors and\/or bevacizumab. The MTD was 400 mg. The most common adverse events included anemia (82.9%), neutropenia (82.9%), fatigue (82.9%), and nausea (77.1%). The overall RR was 79.3%, with a stable disease rate of 18%, resulting in a clinical benefit rate of 96.6%. Median PFS was 11.4 months. RR and PFS did not differ based on the number of lines of prior chemotherapy or prior maintenance therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>This work demonstrates that the combination of ribociclib with chemotherapy in ovarian cancer is feasible and safe. With a clinical benefit rate of 97%, this work provides encouraging evidence of clinical efficacy in patients with recurrent platinum-sensitive disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT03056833.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUNDING<\/jats:title>\n                    <jats:p>This investigator-initiated trial was supported by Novartis, which provided drugs and funds for trial execution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1172\/jci.insight.160573","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T12:00:44Z","timestamp":1660651244000},"source":"Crossref","is-referenced-by-count":17,"title":["Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer"],"prefix":"10.1172","volume":"7","author":[{"given":"Lan G.","family":"Coffman","sequence":"first","affiliation":[{"name":"Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA."},{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."},{"name":"Division of Hematology\/Oncology, Department of Medicine, Hillman Cancer Center, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor J.","family":"Orellana","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshi","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard G.","family":"Frisbie","sequence":"additional","affiliation":[{"name":"Department of Integrative Systems Biology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Normolle","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-4328","authenticated-orcid":true,"given":"Kent","family":"Griffith","sequence":"additional","affiliation":[{"name":"Center for Cancer Data Sciences, Rogel Cancer Center, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-6948","authenticated-orcid":true,"given":"Shitanshu","family":"Uppal","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7833-1967","authenticated-orcid":true,"given":"Karen","family":"McLean","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Berger","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Boisen","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Courtney-Brooks","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Lesnock","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haider","family":"Mahdi","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Olawaiye","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paniti","family":"Sukumvanich","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-9790","authenticated-orcid":true,"given":"Ronald","family":"Buckanovich","sequence":"additional","affiliation":[{"name":"Magee-Womens Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA."},{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA."},{"name":"Division of Hematology\/Oncology, Department of Medicine, Hillman Cancer Center, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"232","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456"},{"key":"B4","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the results of treatment in gynecological cancer","volume":"95 Suppl 1","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.07.005"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.07.010"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.004"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30279-6"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29213"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388298"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5476"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0264"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3157"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.11.006"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2307"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24585"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000926"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1161"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0790"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.01177.x"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3844"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70049-X"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2307\/2531628"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/160573\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:29:27Z","timestamp":1779146967000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/160573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":36,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9,22]]},"published-print":{"date-parts":[[2022,9,22]]}},"alternative-id":["10.1172\/jci.insight.160573"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.160573","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"article-number":"e160573"}}